Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Teel Randy reported acquisition or exercise transactions in this Form 4 filing.
ARVINAS, INC. President and CEO Randy Teel reported an amended equity award, correcting the size of a previously disclosed grant of restricted stock units (RSUs) made on February 26, 2026.
The corrected grant covers 147,179 RSUs, each representing one share of common stock for no cash payment, under the company’s 2018 Stock Incentive Plan. The RSUs vest in four equal annual installments on February 12 of 2027, 2028, 2029 and 2030, contingent on his continued service. Following this correction, Teel is shown as beneficially owning 296,875 shares after the reported transaction.
The amendment fixes an earlier clerical error that had misstated the award as 147,791 RSUs and adjusts the reported post-transaction holdings to match the accurate grant amount.
Arvinas, Inc. director Briggs Morrison reported an open-market purchase of 20,000 shares of the company’s common stock. The transaction took place on March 6, 2026 at a weighted average price of $13.4035 per share, and increased his direct holdings to 96,021 shares. A footnote explains that the purchase price is a weighted average of multiple trades executed between $13.364 and $13.45 per share.
ARVINAS, INC. executive David K. Loomis, VP and Chief Accounting Officer, reported equity awards granted on February 26, 2026. He acquired a stock option for 18,504 shares and a grant of 12,420 shares of common stock, both at an exercise/issuance price of $0.00 per share.
The 12,420 restricted stock units each represent one future share of common stock and will vest in four equal annual installments on February 26, 2027, 2028, 2029, and 2030, subject to his continued service. The 18,504 option shares vest over four years: one quarter on February 26, 2027, with the remaining shares vesting in equal monthly installments through February 26, 2030, also contingent on continued service.
Cacace Angela M reported acquisition or exercise transactions in this Form 4 filing.
ARVINAS, INC. reported that Chief Scientific Officer Angela M. Cacace received new equity awards on February 26, 2026. She was granted options to purchase 67,000 shares of common stock and 45,000 restricted stock units, each RSU representing one share upon settlement for no cash payment.
The RSUs vest in four equal annual installments on February 26 of 2027, 2028, 2029 and 2030, contingent on continued service. The stock options also vest over four years, with 25% vesting on February 26, 2027 and the remaining shares vesting in equal monthly installments through February 26, 2030, subject to ongoing employment.
ARVINAS, INC. reported that Chief Medical Officer Noah Berkowitz received new equity awards. He was granted stock options for 67,000 shares at an exercise price of $0.0000 per share and 45,000 restricted stock units, each representing one share of common stock upon settlement for no consideration.
The RSUs vest in four equal annual installments on February 26, 2027, 2028, 2029 and 2030, subject to continued service. The option also vests over four years, with one-quarter vesting on February 26, 2027 and the remainder in equal monthly installments through February 26, 2030. Following these grants, Berkowitz directly owns 208,938 shares of common stock.
Saik Andrew reported acquisition or exercise transactions in this Form 4 filing.
Arvinas, Inc. reported that its Chief Financial Officer, Andrew Saik, received equity awards on February 26, 2026. He was granted options to purchase 67,000 shares and 45,000 restricted stock units, both at no cash cost, vesting gradually over four years, contingent on continued service.
Arvinas, Inc. President and CEO Randy Teel reported equity awards from the company. He received a stock option for 218,691 shares at an exercise price of $0.00 per share and a grant of 147,791 restricted stock units, each settling into one common share if vesting conditions are met. Both awards vest over four years starting on February 12, 2027, contingent on his continued service.
Arvinas, Inc. director John G. Houston reported selling a total of 35,297 shares of common stock on February 27, 2026 in three open‑market transactions at prices between $13.14 and $13.24 per share.
According to the footnotes, each sale was made automatically by Arvinas to cover tax withholding obligations tied to the vesting and settlement of previously granted restricted stock units, and the sales did not represent discretionary trades. After these transactions, Houston directly owned 1,122,183 shares of Arvinas common stock.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock tied to tax withholding. On February 23, he sold 1,108 shares of Arvinas common stock at $12.16 per share. The sale was made by the company to cover tax obligations arising from the vesting and settlement of one-half of his restricted stock units granted on February 23, 2024, and did not represent a discretionary trade. After this transaction, Loomis directly holds 29,692 Arvinas common shares.